- 1
- 1 VGF in cerebrospinal fluid, when combined with conventional biomarkers, enhances prediction
- 2 of conversion from mild cognitive impairment to Alzheimer's Disease.
- 3
- Authors: Daniel A. Llano^{1,2}, Priya Devanarayan³, Viswanath Devanarayan^{4,5}, for the Alzheimer's 4 Disease Neuroimaging Initiative (ADNI)* 5 6 1. Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, IL 7 2. Carle Neuroscience Institute, Urbana, IL 8 3. 9 Souderton Area High School, Souderton, PA 4. Charles River Laboratories, Horsham, PA 10 Department of Mathematics, Statistics and Computer Science, University of Illinois at 11 5. 12 Chicago, IL 13 *Data used in preparation of this article were obtained from the Alzheimer's Disease 14 Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators 15 16 within the ADNI contributed to the design and implementation of ADNI and/or provided data 17 but did not participate in analysis or writing of this report. A complete listing of ADNI 18 investigators can be found at: 19 http://adni.loni.usc.edu/wp-content/uploads/how to apply/ADNI Acknowledgement List.pdf 20 Acknowledgments: The authors thank Professor Danielle Harvey from UC Davis for providing 21 22 valuable input regarding the ADNI imaging data. 23 24 Corresponding Author: 25 Daniel Llano MD, PhD, Department of Molecular and Integrative Physiology, University of 26 Illinois at Urbana-Champaign 61801 Disclosures: 27 28 Viswanath Devanarayan is an employee of Charles River Laboratories, and as such owns equity 29 in, receives salary and other compensation from Charles River Laboratories. 30 Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD 31

32 ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the

33 National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering,

- 34 and through generous contributions from the following: AbbVie, Alzheimer's Association;
- 35 Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-
- 36 Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and
- 37 Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.;
- 38 Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research &
- 39 Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.;
- 40 Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research;
- 41 Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging;
- 42 Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian
- 43 Institutes of Health Research is providing funds to support ADNI clinical sites in Canada.
- 44 Private sector contributions are facilitated by the Foundation for the National Institutes of
- 45 Health (www.fnih.org). The grantee organization is the Northern California Institute for
- 46 *Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative*
- 47 Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory
- 48 for Neuro Imaging at the University of Southern California.
- 49

50 Abstract

- 51 Sensitive and accurate biomarkers for the prediction of conversion from mild cognitive
- 52 impairment (MCI) to Alzheimer's Disease (AD) are needed to both support clinical care and
- enhance clinical trial design. Here, we examined the potential of cerebrospinal fluid (CSF) levels
- of a peptide derived from a neural protein involved in synaptic transmission, VGF (a non-
- 55 initialism), to enhance accuracy of prediction of conversion from MCI to AD. The performance
- of conventional biomarkers (CSF A β 1-42 and phosphorylated tau +/- hippocampal volume) was
- 57 compared to the same biomarkers with CSF VGF peptide levels. It was observed that VGF
- 58 peptides are lowered in patients with AD compared to controls and that combinations of CSF
- 59 A β 1-42 and phosphorylated tau, hippocampal volume and VGF peptide levels outperformed
- 60 conventional biomarkers alone (hazard ratio = 2.2 vs. 3.9). VGF peptide levels were correlated
- 61 most strongly with total tau levels, but not hippocampal volume, suggesting that they serve as a

3

62	marker for neuronal	l degradation, b	out not necessaril	y in the	hippocampus.	The latter point
----	---------------------	------------------	--------------------	----------	--------------	------------------

63 suggests that VGF may serve as a more general marker of neurodegeneration. Future work will

be needed to determine the specificity of VGF for AD vs. other neurodegenerative diseases.

65

Introduction

Alzheimer Disease (AD) is characterized by a long prodromal course during which a number of 66 67 pathological changes occur prior to the onset of clinical symptoms. Classically, these changes include the deposition of amyloid beta $(A\beta)$ and phosphorylated tau (pTau) into the brain, 68 hippocampal atrophy and disruptions of metabolism, particularly in the temporal and parietal 69 70 cortices (for review of preclinical pathology and biomarkers, please see [1]). It is speculated that 71 these biomarkers are part of a cascade whereby Aβ triggers a series of pathological events, 72 leading to neuronal dysfunction, hyperphosphorylation of tau and consequent synaptic loss, 73 leading to volume loss and metabolic disruption [2-4]. These changes have formed the basis for 74 the use of a series of fluid and imaging biomarkers to facilitate clinical and research practice.

75

AD biomarkers may be used to 1) achieve earlier diagnoses for patients, 2) predict which 76 77 individuals are most likely to clinically worsen over time, 3) help to identify and stratify subjects enrolling in AD-related clinical trials and 4) serve as outcome measurements in AD-related 78 clinical trials [5-7]. For example, there is a 10-15% misdiagnosis rate when AD is diagnosed on 79 clinical grounds only. This high rate of misdiagnosis has substantial cost implications [8-11] and 80 if such misdiagnosed subjects are enrolled into clinical trials, they could obscure the impact of 81 disease-modifying therapy. In addition, prediction of clinical decline in subjects with early-stage 82 disease will permit the institution of aggressive interventions, such as physical exercise or 83 84 pharmacologic therapy, to stave off AD symptoms. Finally, novel biomarkers or combinations of biomarkers could be used to enrich MCI clinical trials with subjects with high conversion rates to 85 shorten and diminish the cost of clinical trials [12, 13]. Therefore, a better understanding of how 86 biomarkers delineate disease classes and predict progression is needed. 87

88

89 Recently, our group and others have identified a group of novel plasma and cerebrospinal fluid

90 (CSF) biomarkers that fall outside the traditional A β cascade. Many of these markers have been

shown to be useful in the prediction of MCI to AD conversion [14-20]. For example, we used a

hypothesis-free bioinformatics approach to identify a panel of 16 peptides in CSF initially
identified as showing high diagnostic accuracy for AD vs. control, that was highly predictive of
conversion from mild cognitive impairment (MCI) to AD in an independent group of subjects
and outperformed conventional CSF markers such as Aβ, tau derivatives and their ratios [20].
These studies highlight non-canonical pathological cascades that may both provide useful tools
for clinical practice and clinical trials purposes, and may also reveal new insights about disease
mechanisms underlying AD.

99

One of the peptides identified using this hypothesis-free approach to separate AD from normal 100 (NL) controls was VGF [20]. VGF (a non-initialism) has recently received significant attention 101 because of its role in learning and memory and potential role in the pathophysiology of AD [21, 102 103 22]. VGF is a neurotrophin-inducible 615-amino acid polypeptide secreted by neurons and is cleaved into multiple smaller fragments ranging in length from 16-129 amino acids. VGF is 104 105 produced in a number of brain regions, including the cerebral cortex, amygdala, hippocampus and hypothalamus, as well as in neuroendocrine tissues such as the adrenal medulla and 106 107 adenohypophysis, and is thought to be involved in synaptogenesis and energy homeostasis [23, 24]. We and others have observed altered levels of VGF in the CSF of AD patients compared to 108 109 controls, though not all studies had the same directionality (studies showing a decrease: [25-31], study showing an increase: [32]). VGF overexpression also protects against memory impairment 110 111 in 5xFAD transgenic mice that model AD [21]. However, previous work has not yet examined the potential for VGF in the CSF, when combined with established biomarkers, to predict MCI to 112 113 AD conversion. It should not be assumed that VGF independently contributes to the prediction of MCI to AD conversion: it is possible that it is a redundant marker for a process already 114 115 encoded by changes in a more conventional biomarker.

116

117 Therefore, in the current study, we examined the potential for VGF in the CSF, when combined 118 with conventional biomarkers of CSF A β 1-42, total tau (tTau) and pTau-181 and hippocampal 119 volume, to enhance the diagnostic and prognostic accuracy of these markers. The focus of this 120 work is on the VGF peptide fragment with sequence NSEPQDEGELFQGVDPR ("VGF.NSEP") 121 since it previously emerged as a strong predictor in a panel of peptides that predict MCI to AD 122 conversion [20], though other VGF peptide fragments are also examined. Unlike our previous

studies involving hypothesis-free approaches to identify optimal peptides to include in biomarker signatures [20, 33, 34], the current study was focused on the utility of VGF. Using data from two 124 independent groups in the ADNI cohort: one group of AD and control subjects and a separate 125

group of MCI subjects, it was found that VGF, when combined with conventional biomarkers, 126

enhanced both the diagnostic accuracy of these markers and the ability of these markers to 127

predict MCI to AD conversion. 128

129

123

130

Methods

Methods and data used for this research are similar to those used in Devanarayan et al. [33]. The 131 ADNI database (adni.loni.usc.edu) utilized in this research was launched in 2003 as a public-132 private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of 133 134 ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessments can be combined to measure the progression of MCI and early 135 136 AD. For up-to-date information, see www.adni-info.org. This study was conducted across multiple clinical sites and was approved by the Institutional Review Boards of all of the 137 138 participating institutions. Informed written consent was obtained from all participants at each site. Data used for the analyses presented here were accessed on February 24, 2018. Although the 139 140 ADNI database continues to be updated on an ongoing basis, most newly added biomarker data 141 are from later time points (i.e., beyond 1 year), in contrast to the baseline data used in this study. 142

Subjects: 143

144 This research was focused on the relationship between VGF, conventional biomarkers (CSF

amyloid/tau and MRI hippocampal volume [HV]) and therefore, only those subjects whose 145

146 values for these markers were available at baseline were included in this study. Ultimately, this

147 dataset included 287 subjects across the three diagnostic categories (AD, MCI and NL). NL

subjects were defined as those without memory complaints and had a clinical dementia rating 148

(CDR) score of 0. MCI subjects had CDR scores of 0.5, had an abnormal score on Wechsler 149

Memory Scale Revised- Logical Memory II and did not have significant functional impairment. 150

151 AD subjects had functional decline and a CDR score of 0.5 or 1.0.

152

Hippocampal volume: 153

6

- 154 HV was chosen given its robust ability to predict MCI to AD conversion [35, 36] and its
- incorporation into proposed schema to classify AD subjects [37]. HV was obtained from MRI
- scans (mostly 1.5T; 25% in this dataset had 3.0T scans) and was computed using FreeSurfer
- 157 software. Please see "UCSF FreeSurfer Methods" PDF document under "MR Image Analysis" in
- the ADNI section of <u>https://ida.loni.usc.edu/</u>) for details as well as [38-40].
- 159

160 CSF Samples:

- 161 Innogenetics' INNO-BIA AlzBio3 immunoassay on a Luminex xMAP platform (see [41] for
- details) was used to measure levels of the conventional biomarkers A β 1-42, tTau, and pTau-181
- in CSF. The Caprion Proteomics mass spectrometry platform was used to measure levels of
- 164 individual peptides. The VGF peptides (sequence NSEPQDEGELFQGVDPR, referred to here as
- 165 VGF.NSEP, sequence AYQGVAAPFPK, referred to here as VGF.AYQG and sequence
- 166 THLGEALEPLSK, referred to here as VGF.THLG) used in this study were among a total of 320
- 167 peptides generated from tryptic digests of 143 proteins. Details regarding the measurements of
- these peptides can be found in the Use of Targeted Mass Spectrometry Proteomic Strategies to
- 169 Identify CSF-Based Biomarkers in Alzheimer's Disease Data Primer (found under Biomarkers
- 170 Consortium CSF Proteomics MRM Data Primer at ida.loni.usc.edu) and in [19].
- 171

172 Statistical Methods:

- 173 As we have described previously [33], optimal combinatorial signatures including CSF A β 1-42,
- tTau, pTau-181, their ratios, HV and VGF-derived peptides with simple decision thresholds for
- each marker were first identified from the AD and NL subjects. These signatures were revealed
- by an unbiased, data-driven manner via regression and tree-based computational algorithms
- 177 called Patient Rule Induction Method [42] and Sequential BATTing [43]. To measure the
- 178 performance of each signature for disease-state differentiation (i.e., NL vs. AD), five-fold cross-
- validation was performed. To do this, the data were randomly divided into five subgroups,
- 180 referred to as folds, and a signature was derived from the remaining four folds. This signature
- 181 was then tested on the left-out fold. This process was repeated for 10 iterations and median
- 182 performance of each performance of positive predictive value (PPV), negative predictive value
- 183 (NPV) and accuracy was computed.

185	Once an optimal signature for differentiating NL from AD was derived, it was tested on a		
186	different group of 135 MCI subjects from the ADNI dataset. Baseline values for A β 1-42, tTau,		
187	pTau-181, HV and VGF peptides for each MCI subject at baseline were used to classify each		
188	subject as being "signature positive" (i.e., similar to the profile found in AD) or "signature		
189	negative" (i.e., similar to the profile found in NC). PPV, NPV and accuracy were then computed		
190	by comparing the actual outcome (conversion or not to AD over 36 months) to the predicted		
191	outcome (signature positive/negative which would predict conversion/nonconversion,		
192	respectively). Exact McNemar's test was used to compare PPV, NPV and accuracy.		
193			
194	In addition to measuring the performance of whether MCI subjects would convert over 36		
195	months, time to conversion was also computed using available data up to 10 years after the initial		
196	evaluation. Potential markers for this analysis were grouped into categories:		
197			
198	1. Demographic markers (presence of APO-E4 allele, age, gender, education)		
199	2. Demographic markers + HV		
200	3. Demographic markers + amyloid/tau CSF markers (heretofore called "AT": Aβ1-42,		
201	tTau, pTau-181, ratios of tTau to A β 1-42 & pTau-181 to A β 1-42)		
202	4. Demographic markers + HV + AT		
203	5. Demographic markers + HV + AT + VGF		
204			
205	All analyses related to predictive modeling and signature derivation were carried out using R		
206	(http://www.R-project.org), version 3.4.1, with the publicly available package, SubgrpID [43].		
207	The time to progression analysis of the derived signatures and related assessments were carried		
208	out using JMP®, version 13.2.		
209			
210	Results:		
211	Demographics:		
212	Similar to Devanarayan et al. (2019), 66 AD, 135 MCI and 86 NL subjects were included in the		
213	analysis and their demographic information and rates of conversion from MCI to AD are shown		
214	in Table 1. There were no statistically significant differences in terms of age or education (range		
215	of means = 75.1 to 75.8 years, p>0.05) and education (range of means = 15.1 to 16 years,		

8

- 216 p>0.05). There was a greater number of males than females (59.1 vs 40.9%), though their
- 217 likelihood of conversion from MCI to AD over 36 months was similar (43.5% vs. 53.9%,
- 218 p=0.285, Chi-squared test). The likelihood that an APO-E4 allele was present was higher AD
- than in other subjects (present in 71.2% AD, 50% MCI and 24.4% NL subjects, p < 0.0001, Chi-
- squared test) and was a relatively weak risk factor for the conversion of MCI to AD (present in
- 40/62 converters and 31/70 non-converters p=0.03, Chi-squared test), both of which have been
- demonstrated previously [44-46].
- 223

224 *Disease state classification – univariate analysis:*

Figures 1A-D recapitulates previous analyses by us and others [33, 47-49] showing that A β 1-42,

tTau, pTau-181 and HV are all significantly different in NL and AD subjects and that these

values are intermediate for MCI subjects. For all four markers in Figures 1A-D, comparisons of

the means between NL and AD groups reveal highly significant differences (p<0.0001 in all

cases). However, it should be noted that there is substantial overlap between the distributions in

each diagnostic category, rendering these biomarkers unsuitable for use in isolation for

- diagnostic categorization. As shown in Figures 1E-F, CSF VGF.NSEP levels are depressed in
- AD patients compared to NL subjects (p=0.0002) and lower levels at baseline are found in future
- 233 MCI-AD converters than nonconverters (p=0.032).
- 234

235 *Disease state classification – multivariate analysis:*

To determine if combinations of conventional biomarkers +/- the VGF.NSEP peptide are useful 236 237 in disease-state classification, data-driven algorithms were used to derive the optimal signature that distinguished NL, MCI and AD. The performances of these signatures are summarized in 238 239 Table 2. The signatures are grouped into six different categories, as described in the Methods 240 section, and took relatively simple forms. The best performing signature for disease-state classification was a combination of HV + APO-E4 status, with an accuracy of 79.6%. Adding 241 conventional CSF markers (A\beta1-42, tTau and pTau-181 and their ratios) did not enhance this 242 value (accuracy = 76.3%), nor did the addition of VGF.NSEP peptide (accuracy = 75.7%). 243

244

245 *Prediction of the likelihood of MCI to AD progression:*

As described above, for disease state classification, no advantage was found when adding the 246 VGF.NSEP peptide to the conventional markers (overall accuracy of 76.3% vs. 75.7%, p > 0.05). 247 248 However, the combined biomarkers signature (HV+AT+VGF) significantly outperformed conventional biomarkers (HV+AT) for the prediction of MCI to AD conversion over 36 months 249 (p=0.00013). Most of the impact of the addition of VGF was in increasing the NPV (from 70.2%) 250 to 79.2%, p<0.0001) while the impact on PPV was more modest (60.2% to 62.1%, p=0.008). 251 252 The signature derived from the conventional and novel markers took a simple form based on only a few markers, with a cut-point on each of them; HV < 7.81 cm³, pTau < 16.18 pg/mL, ratio 253 of tTau to $A\beta 1-42 > 0.29$ and VGF.NSEP peptide < 20.39 intensity units. Thus, the addition of a 254 255 novel VGF peptide to the conventional AD markers provides a simple biomarker that improves the prediction of 36-month disease progression in MCI subjects at baseline. 256

257

258 *Prediction of time to AD progression from MCI:*

Using available information containing 3-10 year follow-up clinical data, future time to 259 progression was computed using the optimal signatures defined above. Table 3 includes a 260 261 summary of the median times to progression of the signature negative and signature positive subjects and the overall hazard ratios with 95% confidence intervals. All groups containing 262 263 conventional biomarkers (combinations of CSF amyloid/tau, HV and APO-E4 status) had similar times to progression (range for 2^{nd} quartile or median = 25.7-31.5 months for signature positive 264 265 subjects) and hazard ratios (range = 1.9-2.2). By comparison, the signature containing VGF.NSEP + conventional markers performed considerably better with median time to 266 267 progression of 24.1 months and 96.2 months for the signature positive and signature negative groups respectively, and hazard ratio of 3.9. This difference in hazard ratio is illustrated in 268 269 Figure 2A (without VGF) and Figure 2B (with VGF), where Kaplan-Meier curves demonstrate 270 time to progression profiles of the signature positive versus signature negative MCI subjects at baseline. The increased separation of the time to progression curves in Figure 2B (with VGF) 271 demonstrates the faster progression experienced by the MCI subjects meeting this signature 272 273 criterion at baseline.

274

275 *Studies of VGF peptide:*

In further evaluation of the VGF.NSEP peptide, we find that its levels are significantly correlated 276 with pTau-181 and tTau in NL, MCI and AD subjects, and not significantly correlated with AB1-277 42 and brain HV in any of the three groups (see Figures 3A-D). To determine if the impact of 278 279 VGF was isolated to the particular peptide fragment (VGF.NSEP) that emerged from the multivariate analysis in Llano et al (2017), the other two VGF peptides (AYQGVAAPFPK, 280 281 referred to as VGF.AYQG and THLGEALAPLSK, referred to as VGF.THLG) in this 320peptide MRM panel were also assessed. The pairwise correlations are over 97% between the 282 283 three VGF peptides (Figure 4), and therefore as expected, the other two VGF peptides have very 284 similar effects across the disease states (NL vs. AD significant with p<0.05) and significantly different (p < 0.05) between the stable and progressive MCI groups (Figures 5 A-D). When 285 replacing the VGF.NSEP peptide by each of these other two peptides one at a time, the 286 performance of the combined signature for the HV+AT+VGF scenario was quite similar in terms 287 288 of the median time to progression of MCI subjects to AD (see Table 4 and Figure 6). However, the differences were greater in the overall time course of progression that resulted in larger 289 290 hazard ratios (4.1 and 4.7). Thus, the considerable improvement we see in the prediction of MCI to AD progression by including VGF with the conventional markers is consistently evident for 291 all three peptide fragments of VGF, and not isolated to a specific peptide fragment. 292

- 293
- 294

Discussion

295 Summary:

Here, we examined the ability of CSF VGF-derived peptides, in combination with conventional 296 297 AD biomarkers (AB1-42, tTau, pTau-181, their ratios and HV) to serve as a disease-state marker to distinguish between AD and NLn subjects, and to predict conversion from MCI to AD in a 298 299 separate group of subjects. We observed that CSF levels of a VGF peptide, on its own, are lower in AD subjects than NLs and that lower levels predict MCI to AD conversion. When combined 300 with conventional biomarkers, the VGF peptide significantly increased the ability of a 301 combination of conventional biomarkers to predict MCI to AD conversion, with the hazard ratio 302 increasing from 2.2 to 3.9. These data suggest that VGF may play a previously under-recognized 303 304 role in the pathophysiology of AD and that CSF VGF may be useful to help predict MCI to AD 305 conversion.

11

306 Total tau vs. phosphorylated tau in predicting MCI to AD conversion:

It is notable that, when combined with HV, Aβ1-42 and VGF.NSEP, CSF tTau was found to 307 308 more strongly predict MCI to AD conversion than pTau-181. tTau, but not pTau-181, elevations in the CSF have been observed in many non-AD conditions involving neuronal injury, including 309 310 stroke, traumatic brain injury, Creutzfeldt-Jacob disease, multiple sclerosis as well as vascular dementia [50-55], suggesting that tTau is a general marker of neuronal injury, while pTau-181 311 312 better reflects AD pathology. The finding in the current study that tTau is more strongly predictive of MCI-AD conversion than pTau-181 is consistent with previous data showing that 313 314 total tau is more predictive than pTau-181 in predicting subsequent cognitive decline in MCI and AD [56, 57]. These findings suggest that while pTau-181 may be more useful as a disease-state 315 316 marker, particularly when making a differential diagnosis, that tTau may be a better marker of disease activity and thus the current rate of clinical decline. In addition, because the database we 317 used only captures the progression to AD of these MCI subjects, and not the other 318 neurodegenerative diseases, is likely that the use of pTau-181 instead of tTau in our signature 319 320 may have shown improved performance specificity if we had applied it to a broader group of MCI subjects that also experienced progression to the other forms of dementia. 321

322 *VGF and AD*:

323 The current finding that all peptides associated with VGF are diminished in the CSF of AD patients compared to controls is consistent with multiple previous studies comparing VGF 324 325 peptide or protein levels in CSF [26-30, 32] and brain tissue (parietal cortex [22]) from AD and 326 control subjects. The functional significance of this decrease is not yet clear but may relate to 327 VGF's potential role in synaptic plasticity and/or neuronal metabolism. VGF is found widely throughout the brain, including areas highly affected in AD such as cerebral cortex, 328 329 hippocampus, entorhinal cortex, basal forebrain, amygdala, and brainstem [22, 58, 59]. Its expression is upregulated by neuronal activity [60] and can be induced by neuronal growth 330 331 factors such as brain-derived neurotrophic factor (BDNF [58, 61]). In animal models, VGF has 332 been shown to be important for the mediation of synaptic plasticity and neurogenesis in the hippocampus [58, 61-63], and knock out of this gene has been shown to cause significant 333 anorexia [64], while overexpression may protect the brain against AD-related pathology [21]. 334

12

These functions align well with the loss of hippocampal function and significant anorexia seen inAD [65, 66].

The mechanism behind the drop in VGF levels in AD CSF is not yet clear. Given the parallel 337 drop in the cerebral cortex [22], low levels in the CSF are likely not due to a shift of VGF from 338 CSF to parenchyma, as has been hypothesized for the low levels of A β in the CSF of AD patients 339 [67]. Low levels of VGF in CSF (and brain) may suggest that VGF is a general marker for 340 341 neuronal loss, consistent the drop in CSF VGF in frontotemporal dementia [68], as such, potentially putting VGF into the "neurodegenerative/neuronal injury" class of biomarkers in the 342 AT(N) framework previously described [69]. This notion that low CSF VGF may be a reflection 343 of neuronal damage is consistent with the current data which demonstrate that VGF levels are 344 345 correlated with hippocampal volume as well as tTau and pTau-181 levels (Figure 3). Future work examining VGF across other states of neuronal injury may help to add clarity to this issue. 346 One previous study observed borderline elevations of VGF in the CSF of MCI compared to 347 control and AD subjects, and that VGF elevations in MCI subjects predicted later conversion to 348 AD [32]. Such transient elevations are reminiscent of "pseudonormalization" of other biomarkers 349 whose values in MCI appear to change in the opposite direction of that seen in AD [20, 34, 70]. 350 It is not clear from the Duits et al. report which specific peptides were elevated in MCI, though 351 the two peptides examined in their study (NSEPQDEGELFQGVDPR and AYQGVAAPFPK) 352 353 matched two of the three peptides in the current study, all of which showed decreases in MCI

and AD (Figure 5). The source of the apparent discrepancy is not yet clear, though we note that

all analytes, not just VGF, in the Duits et al. study showed elevations in the MCI group. It is

notable that other analytes that are elevated in MCI subjects in the Duits et al. study such asChromogranin A have been found to be unchanged in other studies [71] or, in the case of VGF,

decreased in MCI patients that convert to AD [27], suggesting a more general difference in the

databases or the analytical methodologies used between the Duits et al. study and other studies.

360 *Implications of the prediction of MCI-AD conversion:*

361 CSF A β 1-42 and tau derivatives as biomarkers are well-established for the prediction of clinical

decline in MCI [72-76] (for meta-analyses see [77, 78]). In addition, predictive accuracy of these

markers increases when they are combined with volumetric imaging markers [79-83]. Both of

these findings were reproduced in the current study (Table 2). In addition, recently a number of 364 non-A β , non-tau CSF markers have been found, often using proteomic approaches, that separate 365 366 AD from NL subjects, and these markers have been implicated across a number of metabolic, inflammatory and synaptic physiology pathways [25-29, 31, 84-90]. A small number have also 367 shown the ability to predict MCI to AD conversion. For example, heart fatty acid binding 368 369 protein, chemokine receptor 2, neurogranin, calbindin, IL-1, thymus-expressed chemokine have all individually been shown to predict MCI to AD progression [14-20]. In addition, we and 370 others identified panels of peptides that predict MCI to AD progression [19, 20]. These data 371 point to a range of potential pathophysiological mechanisms implicated in AD outside of the 372 classical amyloid-driven cascade. It will be important to replicate the findings in this study as 373 well as others in independent cohorts. In addition, like most of the previous work, the current 374 375 study did not examine non-AD dementia or other neurologic disease. This absence is particularly important in the current study which shows VGF levels that correlate with tTau levels (a marker 376 377 of neurodegeneration, as described above) but not hippocampal volume (Figures 3C and D). These data suggest that VGF levels may correlate with a more general neurodegenerative 378 379 phenotype. Therefore, it will be important in future studies to include non-AD dementias as well as other neurological illness such as stroke or encephalitis, to determine the specificity of VGF as 380 381 a biomarker for AD and predictor of MCI to AD progression. 382 **Figure legends:** 383 384 **Figure 1:** Distributions of biomarkers of in NL, MCI and AD subjects: A) HV, B) A β 1-42, C) 385 386 tTau, D) pTau-181, E) VGF.NSEP levels (shown in normalized and log2 transformed intensity 387 units) and F) baseline VGF.NSEP levels in MCI to AD converters and stable MCI subjects over 388 36 months. In A-E, for the MCI subjects, those that progressed to AD over 36 months are shown in red. The bottom and top ends of the box represent the first and third quartiles respectively, 389

390 with the line inside the box representing the median. Lines extending out of the ends of the box

indicate the range of the data, minus the outliers. The points outside the lines are the low and

392 high outliers.

Figure 2: Time to progression profiles of the signature positive versus signature negative MCI 394 subjects with the shaded 95% confidence intervals are shown here via Kaplan-Meier analysis. 395 396 The effect of signature based on only the conventional markers (HV and AT) is illustrated in 397 Figure 2A and the signature with both the conventional markers and the novel VGF.NSEP peptide from the MRM panel is shown in Figure 2B. Patients meeting the signature criterion that 398 includes the VGF.NSEP peptide experience 3.9-fold faster progression to AD (hazard ratio = 399 3.9), relative to the 2.2-fold faster progression without this peptide. 400 401 Figure 3: Correlation of the VGF.NSEP peptide levels (shown in normalized and log2 402 transformed intensity units) versus conventional markers of AD, brain hippocampal volume HV 403 (A), A_β1-42 (B), pTau-181 (C), and tTau (D), with the least squares regression lines overlaid on 404

individual subject results from the three groups; Normal (in green), MCI (in blue) and AD (in

red). The rank correlation values for each of the groups are shown, with * representing

407 significant correlations (p < 0.05).

408

Figure 4: Scatterplot matrix with rank correlation values overlaid for the three VGF peptides
levels (shown in normalized and log2 transformed intensity units) from the 320-peptide MRM
panel for all subjects.

412

Figure 5: A) Distribution of VGF.AYQG peptide (shown in normalized and log2 transformed
intensity units) is shown across the NL, MCI and AD groups, and B) among the baseline MCI
subjects that either progressed to AD or remained stable over the next 36 months. C) Distribution
of VGF.THLG peptide (shown in normalized and log2 transformed intensity units) is shown
across the NL, MCI and AD groups, and D) among the baseline MCI subjects that either
progressed to AD or remained stable over the next 36 months.

419

Figure 6: Time to progression profiles for the two additional VGF peptides + conventional
biomarkers: (A) AT+HV+VGF.AYQG and (B) AT+HV+VGF.THLG. In both cases, the

signature positive versus signature negative MCI subjects with the shaded 95% confidence

423 intervals are shown via Kaplan-Meier analysis.

425 **References:**

426	1.	Dubois, B., et al., Preclinical Alzheimer's disease: definition, natural history, and
427		diagnostic criteria. Alzheimer's & Dementia, 2016. 12(3): p. 292-323.
428	2.	Bloom, G.S., Amyloid- β and tau: the trigger and bullet in Alzheimer disease
429		pathogenesis. JAMA neurology, 2014. 71(4): p. 505-508.
430	3.	Haass, C. and D.J. Selkoe, Soluble protein oligomers in neurodegeneration: lessons from
431		the Alzheimer's amyloid β -peptide. Nature reviews Molecular cell biology, 2007. 8 (2): p.
432		101.
433	4.	Sengupta, U., A.N. Nilson, and R. Kayed, <i>The role of amyloid-β oligomers in toxicity</i> ,
434		propagation, and immunotherapy. EBioMedicine, 2016. 6: p. 42-49.
435	5.	Blennow, K., et al., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.
436		Nature Reviews Neurology, 2010 . $6(3)$: p. 131.
437	6.	Perrin, R.J., A.M. Fagan, and D.M. Holtzman, Multimodal techniques for diagnosis and
438		prognosis of Alzheimer's disease. Nature, 2009. 461(7266): p. 916.
439	7.	Dubois, B., et al., Research criteria for the diagnosis of Alzheimer's disease: revising the
440		NINCDS-ADRDA criteria. The Lancet Neurology, 2007. 6(8): p. 734-746.
441	8.	Rasmusson, D., et al., Accuracy of clinical diagnosis of Alzheimer disease and clinical
442		features of patients with non-Alzheimer disease neuropathology. Alzheimer disease and
443		associated disorders, 1996. 10(4): p. 180-188.
444	9.	Kirson, N., et al., Excess costs associated with misdiagnosis of Alzheimer's disease
445		among US Medicare beneficiaries with vascular dementia or Parkinson's disease.
446		Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2013. 9(4): p.
447		P845-P846.
448	10.	Beach, T.G., et al., Accuracy of the clinical diagnosis of Alzheimer disease at National
449		Institute on Aging Alzheimer Disease Centers, 2005–2010. Journal of neuropathology and
450		experimental neurology, 2012. 71(4): p. 266-273.
451	11.	Qian, W., et al., Misdiagnosis of Alzheimer's disease: Inconsistencies between clinical
452		diagnosis and neuropathological confirmation. Alzheimer's & Dementia: The Journal of
453		the Alzheimer's Association, 2016. 12(7): p. P293.
454	12.	Yu, P., et al., Enriching amnestic mild cognitive impairment populations for clinical
455		trials: optimal combination of biomarkers to predict conversion to dementia. Journal of
456		Alzheimer's disease, 2012. 32 (2): p. 373-385.
457	13.	van Rossum, I.A., et al., Biomarkers as predictors for conversion from mild cognitive
458		impairment to Alzheimer-type dementia: implications for trial design. Journal of
459		Alzheimer's Disease, 2010. 20(3): p. 881-891.
460	14.	Westin, K., et al., CCL2 is associated with a faster rate of cognitive decline during early
461		stages of Alzheimer's disease. PloS one, 2012. 7(1): p. e30525.
462	15.	Chiasserini, D., et al., CSF levels of heart fatty acid binding protein are altered during
463		early phases of Alzheimer's disease. Journal of Alzheimer's Disease, 2010. 22(4): p.
464		1281-1288.
465	16.	Olsson, B., et al., Cerebrospinal fluid levels of heart fatty acid binding protein are
466		elevated prodromally in Alzheimer's disease and vascular dementia. Journal of
467		Alzheimer's Disease, 2013. 34 (3): p. 673-679.
468	17.	Kester, M.I., et al., Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in
469		symptomatic Alzheimer disease. JAMA neurology, 2015. 72(11): p. 1275-1280.

470 471 472	18.	Craig-Schapiro, R., et al., <i>Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis</i> . PloS one, 2011. 6 (4): p. e18850.
473	19.	Spellman, D.S., et al., <i>Development and evaluation of a multiplexed mass spectrometry</i>
474	17.	based assay for measuring candidate peptide biomarkers in Alzheimer's Disease
475		Neuroimaging Initiative (ADNI) CSF. Proteomics-Clinical Applications, 2015.
476	20.	Llano, D.A., et al., A multivariate predictive modeling approach reveals a novel CSF
470 477 478	20.	peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression. PloS one, 2017. 12 (8): p. e0182098.
	21.	
479	21.	Beckmann, N.D., et al., <i>Multiscale causal network models of Alzheimer's disease identify</i>
480	22	<i>VGF as a key regulator of disease.</i> bioRxiv, 2018.
481	22.	Cocco, C., et al., Distribution of VGF peptides in the human cortex and their selective
482 483		<i>changes in Parkinson's and Alzheimer's diseases.</i> Journal of anatomy, 2010. 217 (6): p. 683-693.
484	23.	Levi, A., et al., Processing, distribution, and function of VGF, a neuronal and endocrine
485		<i>peptide precursor</i> . Cellular and molecular neurobiology, 2004. 24 (4): p. 517-533.
486	24.	Salton, S.R., et al., VGF: a novel role for this neuronal and neuroendocrine polypeptide
487		<i>in the regulation of energy balance</i> . Frontiers in neuroendocrinology, 2000. 21 (3): p.
488		199-219.
489	25.	Wijte, D., et al., A novel peptidomics approach to detect markers of Alzheimer's disease
490		<i>in cerebrospinal fluid</i> . Methods, 2012. 56 (4): p. 500-507.
491	26.	Hendrickson, R.C., et al., High resolution discovery proteomics reveals candidate disease
492		progression markers of Alzheimer's disease in human cerebrospinal fluid. PloS one,
493		2015. 10 (8): p. e0135365.
494	27.	Jahn, H., et al., Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid:
495		<i>identification and prospective evaluation of new synaptic biomarkers.</i> PloS one, 2011.
496		6 (10): p. e26540.
497	28.	Selle, H., et al., Identification of novel biomarker candidates by differential peptidomics
498		analysis of cerebrospinal fluid in Alzheimer's disease. Combinatorial chemistry & high
499		throughput screening, 2005. 8(8): p. 801-806.
500	29.	Hölttä, M., et al., An Integrated Workflow for Multiplex CSF Proteomics and
501		Peptidomics • Identification of Candidate Cerebrospinal Fluid Biomarkers of
502		Alzheimer's Disease. Journal of proteome research, 2014. 14(2): p. 654-663.
503	30.	Carrette, O., et al., A panel of cerebrospinal fluid potential biomarkers for the diagnosis
504	001	of Alzheimer's disease. PROTEOMICS: International Edition, 2003. 3 (8): p. 1486-1494.
505	31.	Brinkmalm, G., et al., A parallel reaction monitoring mass spectrometric method for
506	011	analysis of potential CSF biomarkers for Alzheimer's disease. PROTEOMICS–Clinical
507		Applications, 2018. 12 (1): p. 1700131.
508	32.	Duits, F.H., et al., Synaptic proteins in CSF as potential novel biomarkers for prognosis
509	52.	<i>in prodromal Alzheimer's disease</i> . Alzheimer's research & therapy, 2018. 10 (1): p. 5.
510	33.	Devanarayan, P., et al., <i>Identification of a simple and novel cut-point based CSF and MRI</i>
511	55.	signature for predicting Alzheimer's disease progression that reinforces the 2018 NIA-
512		AA research framework Journal of Alzheimer's Disease, 2019. In Press.
512	34.	Llano, D.A., et al., Evaluation of plasma proteomic data for Alzheimer disease state
513	54.	classification and for the prediction of progression from mild cognitive impairment to
514		Alzheimer disease. Alzheimer Disease & Associated Disorders, 2013. 27 (3): p. 233-243.
212		<i>Induction ansense.</i> Induction Disease & Associated Disorders, 2013. 21 (3). p. 233-243.

516	35.	Jack, C.R., et al., Prediction of AD with MRI-based hippocampal volume in mild
517	26	<i>cognitive impairment.</i> Neurology, 1999. 52 (7): p. 1397-1397.
518	36.	Risacher, S.L., et al., Baseline MRI predictors of conversion from MCI to probable AD in
519		the ADNI cohort. Current Alzheimer Research, 2009. 6 (4): p. 347-361.
520	37.	Dubois, B., et al., Revising the definition of Alzheimer's disease: a new lexicon. The
521		Lancet Neurology, 2010. 9(11): p. 1118-1127.
522 523	38.	Dale, A.M., B. Fischl, and M.I. Sereno, <i>Cortical surface-based analysis: I. Segmentation and surface reconstruction</i> . Neuroimage, 1999. 9 (2): p. 179-194.
524	39.	Fischl, B., M.I. Sereno, and A.M. Dale, Cortical surface-based analysis: II: inflation,
525		flattening, and a surface-based coordinate system. Neuroimage, 1999. 9(2): p. 195-207.
526	40.	Fischl, B., et al., <i>High-resolution intersubject averaging and a coordinate system for the</i>
527		<i>cortical surface</i> . Human brain mapping, 1999. 8 (4): p. 272-284.
528	41.	Shaw, L.M., et al., <i>Cerebrospinal fluid biomarker signature in Alzheimer's disease</i>
529		neuroimaging initiative subjects. Annals of neurology, 2009. 65(4): p. 403-413.
530	42.	Chen, G., et al., A PRIM approach to predictive-signature development for patient
531	12.	stratification. Statistics in medicine, 2015. 34 (2): p. 317-342.
532	43.	Huang, X., et al., <i>Patient subgroup identification for clinical drug development</i> . Statistics
533	ч.,	in medicine, 2017. 36 (9): p. 1414-1428.
534	44.	Corder, E., et al., <i>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's</i>
535		disease in late onset families. Science, 1993. 261 (5123): p. 921-923.
536	45.	Drzezga, A., et al., <i>Prediction of individual clinical outcome in MCI by means of genetic</i>
537	45.	assessment and 18F-FDG PET. Journal of Nuclear Medicine, 2005. 46 (10): p. 1625-
		1632.
538	46.	Lindsay, J., et al., Risk factors for Alzheimer's disease: a prospective analysis from the
539 540	40.	
540		<i>Canadian Study of Health and Aging</i> . American journal of epidemiology, 2002. 156 (5):
541	17	p. 445-453.
542	47.	Galasko, D., et al., <i>High cerebrospinal fluid tau and low amyloid</i> β <i>42 levels in the</i>
543		clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
544	40	Archives of neurology, 1998. 55 (7): p. 937-945.
545	48.	Tapiola, T., et al., Cerebrospinal fluid β -amyloid 42 and tau proteins as biomarkers of
546		Alzheimer-type pathologic changes in the brain. Archives of neurology, 2009. 66 (3): p.
547	10	382-389.
548	49.	Hampel, H., et al., Value of CSF β -amyloid 1–42 and tau as predictors of Alzheimer's
549		disease in patients with mild cognitive impairment. Molecular psychiatry, 2004. 9(7): p.
550		705.
551	50.	Satoh, K., et al., 14-3-3 protein, total tau and phosphorylated tau in cerebrospinal fluid
552		of patients with Creutzfeldt-Jakob disease and neurodegenerative disease in Japan.
553		Cellular and molecular neurobiology, 2006. 26 (1): p. 45-52.
554	51.	Nägga, K., et al., Cerebrospinal fluid phospho-Tau, total Tau and β -Amyloid1–42 in the
555		differentiation between Alzheimer's disease and vascular dementia. Dementia and
556		geriatric cognitive disorders, 2002. 14(4): p. 183-190.
557	52.	Kapaki, E., et al., Cerebrospinal fluid tau, phospho-tau181 and β -amyloid1– 42 in
558		idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease.
559		European journal of neurology, 2007. 14(2): p. 168-173.

	50	
560	53.	Skillbäck, T., et al., <i>Diagnostic performance of cerebrospinal fluid total tau and</i>
561		phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality
562		<i>Registry</i> . JAMA neurology, 2014. 71 (4): p. 476-483.
563	54.	Hesse, C., et al., Transient increase in total tau but not phospho-tau in human
564		cerebrospinal fluid after acute stroke. Neuroscience letters, 2001. 297(3): p. 187-190.
565	55.	Bartosik-Psujek, H. and Z. Stelmasiak, The CSF levels of total-tau and phosphotau in
566		patients with relapsing-remitting multiple sclerosis. Journal of neural transmission, 2006.
567		113 (3): p. 339-345.
568	56.	Sämgård, K., et al., Cerebrospinal fluid total tau as a marker of Alzheimer's disease
569		intensity. International Journal of Geriatric Psychiatry: A journal of the psychiatry of late
570		life and allied sciences, 2010. 25 (4): p. 403-410.
571	57.	Blom, E.S., et al., Rapid progression from mild cognitive impairment to Alzheimer's
572		disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE $\varepsilon 4/\varepsilon 4$
573		genotype. Dementia and geriatric cognitive disorders, 2009. 27(5): p. 458-464.
574	58.	Alder, J., et al., Brain-derived neurotrophic factor-induced gene expression reveals novel
575		actions of VGF in hippocampal synaptic plasticity. Journal of Neuroscience, 2003.
576		23 (34): p. 10800-10808.
577	59.	Snyder, S.E. and S.R. Salton, <i>Expression of VGF mRNA in the adult rat central nervous</i>
578		system. Journal of Comparative Neurology, 1998. 394(1): p. 91-105.
579	60.	Snyder, S., et al., The messenger RNA encoding VGF, a neuronal peptide precursor, is
580		rapidly regulated in the rat central nervous system by neuronal activity, seizure and
581		<i>lesion</i> . Neuroscience, 1997. 82 (1): p. 7-19.
582	61.	Thakker-Varia, S., et al., <i>The neuropeptide VGF produces antidepressant-like behavioral</i>
583		effects and enhances proliferation in the hippocampus. Journal of Neuroscience, 2007.
584		27 (45): p. 12156-12167.
585	62.	Bozdagi, O., et al., The neurotrophin-inducible gene Vgf regulates hippocampal function
586		and behavior through a brain-derived neurotrophic factor-dependent mechanism. Journal
587		of Neuroscience, 2008. 28 (39): p. 9857-9869.
588	63.	Thakker-Varia, S., et al., VGF (TLQP-62)-induced neurogenesis targets early phase
589		neural progenitor cells in the adult hippocampus and requires glutamate and BDNF
590		<i>signaling</i> . Stem cell research, 2014. 12 (3): p. 762-777.
591	64.	Hahm, S., et al., <i>Targeted deletion of the Vgf gene indicates that the encoded secretory</i>
592		peptide precursor plays a novel role in the regulation of energy balance. Neuron, 1999.
593		23 (3): p. 537-548.
594	65.	Gillette-Guyonnet, S., et al., Weight loss in Alzheimer disease. The American journal of
595		clinical nutrition, 2000. 71 (2): p. 637S-642S.
596	66.	Johnson, D.K., C.H. Wilkins, and J.C. Morris, Accelerated weight loss may precede
597		diagnosis in Alzheimer disease. Archives of neurology, 2006. 63(9): p. 1312-1317.
598	67.	Motter, n., et al., Reduction of β -amyloid peptide 42 in the cerebrospinal fluid of patients
599		with Alzheimer's disease. Annals of Neurology: Official Journal of the American
600		Neurological Association and the Child Neurology Society, 1995. 38 (4): p. 643-648.
601	68.	Rüetschi, U., et al., Identification of CSF biomarkers for frontotemporal dementia using
602		<i>SELDI-TOF.</i> Experimental neurology, 2005. 196 (2): p. 273-281.
603	69.	Jack, C.R., et al., NIA-AA Research Framework: Toward a biological definition of
604		Alzheimer's disease. Alzheimer's & Dementia, 2018. 14(4): p. 535-562.
		- · · · · · · · · · · · · · · · · · · ·

605	70.	Dickerson, B., et al., Increased hippocampal activation in mild cognitive impairment
606		compared to normal aging and AD. Neurology, 2005. 65(3): p. 404-11.
607	71.	Perrin, R.J., et al., Identification and validation of novel cerebrospinal fluid biomarkers
608		for staging early Alzheimer's disease. PloS one, 2011. 6(1): p. e16032.
609	72.	Hansson, O., et al., Association between CSF biomarkers and incipient Alzheimer's
610		disease in patients with mild cognitive impairment: a follow-up study. The Lancet
611		Neurology, 2006. 5 (3): p. 228-234.
612	73.	Forlenza, O.V., et al., Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic
613		accuracy and prediction of dementia. Alzheimer's & Dementia: Diagnosis, Assessment &
614		Disease Monitoring, 2015. 1(4): p. 455-463.
615	74.	Zetterberg, H., LO. Wahlund, and K. Blennow, Cerebrospinal fluid markers for
616		prediction of Alzheimer's disease. Neuroscience letters, 2003. 352(1): p. 67-69.
617	75.	Handels, R.L., et al., Predicting progression to dementia in persons with mild cognitive
618		impairment using cerebrospinal fluid markers. Alzheimer's & Dementia, 2017. 13(8): p.
619		903-912.
620	76.	Lanari, A. and L. Parnetti, Cerebrospinal fluid biomarkers and prediction of conversion
621		in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting.
622		The Scientific World Journal, 2009. 9: p. 961-966.
623	77.	Diniz, B.S., J.A. Pinto Jr, and O.V. Forlenza, Do CSF total tau, phosphorylated tau, and
624		β -amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's
625		disease? A systematic review and meta-analysis of the literature. The World Journal of
626		Biological Psychiatry, 2008. 9(3): p. 172-182.
627	78.	Mitchell, A.J., CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive
628		impairment and Alzheimer's disease-a meta-analysis of 51 studies. Journal of Neurology,
629		Neurosurgery & Psychiatry, 2009.
630	79.	Vemuri, P., et al., MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting
631		future clinical change. Neurology, 2009. 73(4): p. 294-301.
632	80.	Nesteruk, M., et al., Combined use of biochemical and volumetric biomarkers to assess
633		the risk of conversion of mild cognitive impairment to Alzheimer's disease. Folia
634		neuropathologica, 2016. 54 (4): p. 369-374.
635	81.	Bouwman, F., et al., CSF biomarkers and medial temporal lobe atrophy predict dementia
636		in mild cognitive impairment. Neurobiology of aging, 2007. 28(7): p. 1070-1074.
637	82.	Heister, D., et al., Predicting MCI outcome with clinically available MRI and CSF
638		biomarkers. Neurology, 2011: p. WNL. 0b013e3182343314.
639	83.	Westman, E., JS. Muehlboeck, and A. Simmons, <i>Combining MRI and CSF measures</i>
640		for classification of Alzheimer's disease and prediction of mild cognitive impairment
641		conversion. Neuroimage, 2012. 62(1): p. 229-238.
642	84.	Maarouf, C.L., et al., Proteomic analysis of Alzheimer's disease cerebrospinal fluid from
643		neuropathologically diagnosed subjects. Current Alzheimer research, 2009. 6(4): p. 399-
644	~ ~	406.
645	85.	Oláh, Z., et al., Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted
646	0.6	dead or alive. Journal of Alzheimer's Disease, 2015. 44(4): p. 1303-1312.
647	86.	Roher, A.E., et al., <i>Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed</i>
648		Alzheimer's disease. Biomarkers, 2009. 14(7): p. 493-501.


20

- 649 87. Choi, Y.S., et al., *Targeted human cerebrospinal fluid proteomics for the validation of*650 *multiple Alzheimer's disease biomarker candidates.* Journal of Chromatography B, 2013.
 651 930: p. 129-135.
- 88. Wildsmith, K.R., et al., *Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics*. Molecular
 neurodegeneration, 2014. 9(1): p. 22.
- Paterson, R., et al., A targeted proteomic multiplex CSF assay identifies increased malate *dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology*. Translational psychiatry, 2016. 6(11): p. e952.
- Heywood, W.E., et al., *Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.*Molecular neurodegeneration, 2015. 10(1): p. 64.

661


21

663 Figure 1:




22

666 Figure 2:



667

669 Figure 3:





672 Figure 4:








Figure 5: 675



26

678 Figure 6:



7	7
/	
_	

		AD	MCI	NL
		(n=66)	(n=135)	(n=86)
Gender	Μ	37	91	44
(n)	F	29	44	42
Ano E (n)	E4	47	71	21
Apo-E (n)	Non-E4	19	64	65
-	Age (years, Mean +/- SD)		74.8 +/- 7.4	75.8 +/- 5.6
Education (years, Mean +/- SD) MMSE (Mean +/- SD)		15.1 +/- 3	16 +/- 3	15.6 +/- 3
		23.5 +/- 1.9	26.9 +/- 1.7	29.1 +/- 1

681	Table 1: Disease-state demographics
-----	-------------------------------------

		MCI to AD converters	Stable MCI
		(n=64)	(n=71)
Gender	М	40	51
(n)	F	24	20
Аро-Е	E4	40	31
(n)	Non-E4	24	40
1	age ean +/- SD)	74.9 +/- 7.6	74.7 +/- 7.2
	cation ean +/- SD)	15.6 +/- 3.0	16.4 +/- 2.9
	MSE +/- SD)	26.4 +/- 1.7	27.4 +/- 1.6

2	~
/	x
_	-

Data type	Diagnostic Criteria for Signature positive	AD versus Normal Diagnosis (internal cross-validation)			36m MCI Progression to AD (independent validation)			
		% PPV	% NPV	% Accuracy	% PPV (MCI to AD)	% NPV (Stable MCI)	% Accuracy	
AT	tTau / Ab1-42 > 0.59	71.6	80.5	76.5	58.1	66.1	61.7	
HV	HV < 6.41 and ApoE4 +	92.7	74.8	79.6	61.2	60.5	60.7	
AT + HV	HV < 7.0, pTau > 18.1, and tTau / Ab1-42 > 0.36	73.4	78.4	76.3	60.2	70.2	64.4	
VGF	VGF.NSEP < 19.71 and ApoE4 +	69.1	79.1	70.4	65.9	61.5	63.0	
AT + VGF	pTau / Ab1-42 > 0.08, tTau / Ab1-42 > 0.31, and VGF.NSEP < 20.30	75.4	75.8	75.7	59.6	76.1	65.2	
AT + HV + VGF	$\begin{array}{l} HV < 7.81, pTau > 16.18, \\ tTau \ / \ Ab1-42 > 0.29, \ and \\ VGF.NSEP \ < 20.39 \end{array}$	72.3	78.2	75.7	62.1	79.2	68.1	

Table 2: Performance summary of optimal signatures

685

Data type		Sign	ature Negative	Signature Positive		
	Diagnostic Criteria for Signature positive	N	T2P (months) Q1, Q2, Q3	N	T2P (months) Q1, Q2, Q3	Hazard Ratio (95% C.I.)
AT	tTau / Ab1-42 > 0.59	59	23.4, 71.6, 108	76	13.6, 25.7, 72.0	1.9 (1.2, 3.1)
HV	HV < 6.41 and ApoE4 +	86	18.6, 48.2, 108	49	13.1, 31.5, 60.0	2.0 (1.3, 3.2)
AT + HV	HV < 7.0, pTau > 18.1, and tTau / Ab1-42 > 0.36	57	24.4, 71.6, 108	78	12.6, 25.7, 72.0	2.2 (1.4, 3.6)
VGF	VGF.NSEP < 19.71 and ApoE4 +	91	24.0, 48.0, 96.5	44	12.2, 18.1, 71.6	2.1 (1.3, 3.2)
AT + VGF	pTau / Ab1-42 > 0.08, tTau / Ab1-42 > 0.31, and VGF.NSEP < 20.30	46	38.8, 96.5, 108	89	12.6, 24.1, 54.9	3.4 (2.1, 5.9)
AT + HV + VGF	HV < 7.81, pTau > 16.18, tTau / Ab1-42 > 0.29, and VGF.NSEP < 20.39	48	38.8, 96.2, 120	87	12.4, 24.1, 60	3.9 (2.3, 7.0)

Table 3: Time to progression (T2P) of MCI subjects to AD using optimal signatures

688

30

Table 4: Time to progression (T2P) of MCI subjects to AD using optimal and other candidate

691 signatures for the AT+HV+MRM scenario

692

Data type		Sigr	ature Negative	Signature Positive		
	Diagnostic Criteria for Signature positive	N	T2P (months) Q1, Q2, Q3	N	T2P (months) Q1, Q2, Q3	Hazard Ratio (95% C.I.)
AT + HV + VGF	HV < 7.81, pTau > 16.18, tTau / Ab1-42 > 0.29, and VGF.NSEP < 20.39	48	38.8, 96.2, 120	<mark>8</mark> 7	12.4, 24.1, 60.0	3.9 (2.3, 7.0)
	HV < 7.81, pTau > 16.18, tTau / Ab1-42 > 0.29, and VGF.AYQG < 18.47	56	35.8, 96.2, 120	79	12.3, 23.4, 48.3	4.1 (2.4, 6.8)
	HV < 7.81, pTau > 16.18, tTau / Ab1-42 > 0.29, and VGF.THLG < 17.62	52	48.0, 96.5, 120	83	12.3, 23.9, 48.3	4.7 (2.7, 8.2)